Download in electronic PDF format for $75

Abstract:  The development and compounding of pharmacotherapeutic formulations that are suitable for infants and young children can be a challenging problem. This problem results from the lack of knowledge on the acceptability of different dosage forms and formulations to children in relation to age and developmental status, as well as the lack of reliable documentation of formulations used in pediatric clinical trials. As part of its mandate under the Best Pharmaceuticals for Children Act to improve pediatric therapeutics, the National Institute of Child Health and Human Development has sponsored the Pediatric Formulations Initiative. The goal of this ongoing initiative is to address the issues and concerns associated with pediatric therapeutics by convening groups of researchers and experts in pediatric formulations from academia, pharmaceutical companies, the National Institutes of Health, and the U.S. Food and Drug Administration. In this second part of a two-part article, the activities of the various groups that c

Related Keywords: children, pediatric formulations, oral dosage forms, NICHD, liquid formulations, Biopharmaceutical Classification System, patient compliance, flavoring, palatability, drug costs, drug taste, fast-dissolving preparations

Related Categories: LEGAL, PAIN MANAGEMENT, PEDIATRICS, PATIENT COMPLIANCE, DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version